US · USD
BIO-B
Bio-Rad Laboratories Inc
- Day's range
- $365.08 – $365.08
- 52-week range
- $255.54 – $365.08
Follow BIO-B in the Fuolio
See how BIO-B weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountBIO-B in numbers
- Market cap
- $10.1B
- P/E
- 45.42
- P/B
- 1.41
- Dividend yield (12m)
- 0.00%
BIO-B trades at 45.42 times its earnings of the last 12 months.
BIO-B price history
BIO-B risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | +20.43% | +33.73% | -49.98% |
| Volatility (annualized) | 25.29% | 27.85% | 31.73% |
| Largest drawdown | -14.02% | -34.46% | -68.75% |
| Positive months | 7/12 | 20/36 | 27/60 |
How much did investing in BIO-B return?
$1,000.00 invested on 10/01/2021 would be worth $500.21 today.
- Value today in BIO-B
- $500.21
- Return over the period
- -49.98%
- Return per year
- -12.94%
- In the S&P 500
- $1,676.89
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
BIO-B fundamentals
Valuation
- P/E45.42
- P/B1.41
- EV/EBITDA—
- EV/EBIT174.87
- EV/Revenue3.59
- P/EBIT190.23
- P/S3.90
- P/OCF20.51
- P/FCF28.61
- Earnings yield0.57%
- PEG ratio—
- Earnings per share$8.04
- Book value per share$259.28
Debt
- Net debt-$815.5M
- Net debt/EBITDA—
- Net debt/Equity-0.11
- Debt/Equity0.11
- Current ratio3.14
- Quick ratio2.33
- Cash ratio1.68
Efficiency
- Gross margin51.90%
- EBITDA margin—
- Operating margin2.05%
- Net margin8.59%
- Asset turnover0.25
Profitability
- ROE3.10%
- ROA2.17%
- ROIC0.53%
- Payout0.00%
Growth
- Revenue CAGR (5 years)-2.10%
- Earnings CAGR (5 years)-44.03%
- Revenue growth (year)—
- Earnings growth (year)—
- Revenue growth (quarter)—
- Earnings growth (quarter)—
What is BIO-B's fair price?
Two classic value formulas, with today's numbers. The current price is $365.08.
- Graham's fair price
- $216.55
- 40.68% below the price
√(22.50 × $8.04 × $259.28)
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- —
- Does not apply to BIO-B: it paid no distributions in the last five years.
Décio Bazin only bought stocks yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years over 6%.
Graham ignores growth and debt; Bazin assumes past distributions repeat. They are references to compare, not a buy recommendation.
BIO-B's indicators by year
Multiples at each year's closing price; margins and returns from that year's statements.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | 10.20% | -28.07% | -7.29% | -37.73% | 31.09% | 38.57% | 30.55% | 9.09% |
| ROIC | 0.51% | 3.47% | 3.04% | 4.12% | 3.05% | 3.67% | 3.84% | -2.04% |
| Gross margin | 51.87% | 53.73% | 53.42% | 55.93% | 56.05% | 56.49% | 54.38% | 53.43% |
| EBITDA margin | 8.23% | 16.39% | 18.11% | 22.12% | 21.83% | 22.00% | 15.74% | 1.52% |
| Net margin | 29.42% | -71.86% | -23.86% | -129.45% | 145.57% | 149.84% | 76.08% | 15.97% |
| Net debt/EBITDA | -1.59 | -1.10 | -0.84 | -0.96 | -1.35 | -1.75 | -3.03 | -11.68 |
BIO-B's financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | $2.6B | $2.6B | $2.7B | $2.8B | $2.9B | $2.5B |
| Cost of revenue | -$1.2B | -$1.2B | -$1.2B | -$1.2B | -$1.3B | -$1.1B |
| Gross profit | $1.3B | $1.4B | $1.4B | $1.6B | $1.6B | $1.4B |
| EBITDA | $212.6M | $420.6M | $483.7M | $619.9M | $637.9M | $559.9M |
| EBIT | $47.2M | $269M | $337.8M | $482.6M | $500.3M | $421.3M |
| Financial result | — | — | — | — | — | — |
| Income before tax | $995.5M | -$2.3B | -$850.1M | -$4.7B | $5.4B | $4.9B |
| Income tax | -$235.6M | $498.3M | $212.8M | $1.1B | -$1.2B | -$1.1B |
| Net income | $759.9M | -$1.8B | -$637.3M | -$3.6B | $4.3B | $3.8B |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
Does BIO-B pay dividends?
BIO-B has no distributions on record.
About Bio-Rad Laboratories
- Sector
- Manufacturing
Questions about BIO-B
How much is BIO-B today?
BIO-B is at $365.08 (0.00% on the day), last traded on 10/05/2026.
What are the P/E and P/B of BIO-B?
BIO-B trades at a P/E of 45.42 and a P/B of 1.41.
How much did BIO-B return in 12 months?
BIO-B returned 20.43% in 12 months, with annualized volatility of 25.29% and a largest drawdown of -14.02%.